Feher M D, Betteridge D J
Department of Therapeutics, Charing Cross and Westminster Medical School, St. Stephen's Hospital, London, U.K.
Cardiovasc Drugs Ther. 1989 Jun;3 Suppl 1:333-40. doi: 10.1007/BF00148479.
There is now considerable evidence that treatment of abnormalities of lipids and lipoproteins reduces the incidence of coronary heart disease (CHD). Treatment of hypertension, another major cardiovascular risk factor, has not been shown to have the same impact on CHD. Possible explanations for this are that cardiovascular risk factors may occur in combination in an individual or that therapy for hypertension has adversely affected one or several of the other risk factors for CHD, thereby offsetting the benefit gained by lowering blood pressure. This article reviews the relationship between lipids, lipoproteins, and coronary heart disease, and the impact of cholesterol lowering on CHD. The evidence that antihypertensive drugs are associated with lipid and lipoprotein abnormalities is introduced by a critical appraisal of the several studies for such evidence. Implications for the treatment of the hypertensive patient are discussed.
现在有大量证据表明,治疗脂质和脂蛋白异常可降低冠心病(CHD)的发病率。另一个主要的心血管危险因素——高血压的治疗,尚未显示出对冠心病有同样的影响。对此可能的解释是,心血管危险因素可能在个体中同时出现,或者高血压治疗对冠心病的其他一个或几个危险因素产生了不利影响,从而抵消了降低血压所带来的益处。本文综述了脂质、脂蛋白与冠心病之间的关系,以及降低胆固醇对冠心病的影响。通过对几项此类证据研究的批判性评估,介绍了抗高血压药物与脂质和脂蛋白异常相关的证据。讨论了对高血压患者治疗的启示。